Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Discovery of Dual-Acting Biofilm Inhibitors against Pseudomonas aeruginosa by the Coupling of 3‑Hydroxypyridin-4(1<i>H</i>)‑ones with <i>N</i>‑Phenylamide QS Inhibitors by Hao-Zhong Long (19685972)

“…Mechanistic studies revealed that there was a decreased production of virulence regulated by quorum sensing system and a lack of iron acquisition under the treatment of <b>19l</b>, which led to the inhibition of biofilm. …”

Microparticles Engineered to Highly Express Peroxisome Proliferator-Activated Receptor-γ Decreased Inflammatory Mediator Production and Increased Adhesion of Recipient Monocytes by Julie Sahler (666499)

Physiological parameters in control rats treated with medical air and rats treated with argon at 50 vol% before and after MCAO-induced ischemia. by Hélène N. David (331605)

“…Administration of argon at 50 vol% significantly decreases the rats' body temperature by 1.1°C.…”

Myelinopathy results in a significantly reduced spike probability and increased latency after a release event. by Maral Budak (6680351)

Quantile regression results of male triathletes. by Junhui Zhao (626062)

“…Temperature has a positive effect on race times, while altitude also shows a significant positive impact, with race times decreasing as altitude increases (up to 1,600 meters in this study’s dataset). …”

Descriptive statistics for categorical variables. by Junhui Zhao (626062)

“…Temperature has a positive effect on race times, while altitude also shows a significant positive impact, with race times decreasing as altitude increases (up to 1,600 meters in this study’s dataset). …”

List of triathlon events analyzed. by Junhui Zhao (626062)

“…Temperature has a positive effect on race times, while altitude also shows a significant positive impact, with race times decreasing as altitude increases (up to 1,600 meters in this study’s dataset). …”

Descriptive statistics for numerical variables. by Junhui Zhao (626062)

“…Temperature has a positive effect on race times, while altitude also shows a significant positive impact, with race times decreasing as altitude increases (up to 1,600 meters in this study’s dataset). …”

Image_1_Reduced Ca2+ transient amplitudes may signify increased or decreased depolarization depending on the neuromodulatory signaling pathway.PDF by Arunima Debnath (13136676)

Monoclonal antibody inhibition of IL-8 and CXCR2 decreased TFF3 stimulated HUVEC tubule formation <i>in vitro</i>. by Wai-Hoe Lau (825097)

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”

Association between AIP and depression in total people by Siyi Deng (12887198)

Losartan is not neuroprotective in a crush model of axon injury. by Harry A. Quigley (695817)

Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial by Michel Mandro (2637532)

“…The primary endpoint was defined as the probability of being seizure-free at month 4. A secondary endpoint was defined as >50% reduction in seizure frequency at month 4, compared to baseline. …”

Gas exchange model used to construct oxygen-haemoglobin dissociation curves (ODC) for the cohort. by Nikhil Mayor (13989363)

Depletion of <i>cyd-1</i> leads to decreased oocyte quality and increased apoptosis without affecting the DNA damage response (DDR). by Umanshi Rautela (20235283)